Vitiligo+2
RecruitingLong-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials
Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials
- Disease:VitiligoNeurodermatitis+1
- Substances:Povorcitinib
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Povorcitinib
- Sponsor:Incyte Corp.










